GL Globe Life Inc.
Globe Life Inc., through its subsidiaries, provides various life and supplemental health insurance products to lower middle- and middle-income families in the United States. It operates in three segments: Life Insurance, Supplemental Health Insurance, and Investments. The company offers whole, term, and other life insurance products, as well as life insurance for children; Medicare supplement and limited-benefit supplemental health insurance products, such as accident, cancer, critical illness, heart, intensive care, and other health products; and final expense, accidental death, mortgage protection, and hospital insurance products. It sells its products through direct-to-consumer channels, exclusive independent agents, general agency independent agents, and brokers. The company was formerly known as Torchmark Corporation and changed its name to Globe Life Inc. in August 2019. Globe Life Inc. was founded in 1900 and is headquartered in McKinney, Texas.…
Industry Peers
Insurance - LifeKey Statistics
About Globe Life (NYSE: GL)
›
Globe Life (NYSE: GL) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Insurance - Life industry, part of the Financial Services sector, and reports about 3,695 employees.
The shares were at 153.59 USD on 19 November 2026, up 17.0% over 52 weeks. Its 52-week range is 129.21 USD to 191.55 USD: the price is 19.8% below the high and 18.9% above the low.
At a market capitalisation of 11.59B USD, it trades at 10.3 times trailing earnings and 9.4 times forward earnings. The median trailing P/E of its 19 largest Insurance - Life peers is 12.6, a discount of 19% for GL. It pays a dividend yielding 0.85% (it pays out 8% of its earnings), against a median of 2.70% among the dividend payers in that peer group.
Globe Life reports return on equity of 19.4%, an operating margin of 25.8% and revenue up 5.5% year over year.
Its debt exceeds its cash by 3.09B USD, a debt-to-equity ratio of 0.44. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Buy; their mean price target of 185.45 USD is 20.7% above the current price. The next earnings report is expected on 3 February 2027.